IKBKB

Across TCGA pan-cancer cohorts, IKBKB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IKBKB data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher IKBKB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IKBKB expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

SCLC, LUSC, and LUAD are the cancer types where IKBKB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
LUSC	OS	Median	III,IV	0.099	0.691	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	11	view →
BLCA	DFS	Median	III,IV	0.769	0.268	.049	1	view →
STAD	DFS	Median	All	0.878	0.382	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IKBKB–SCLC (OS)

Open the SCLC breakdown →